Answers are grounded in this paper and cite their sources.
In the phase III DESTINY-Breast03 trial, trastuzumab deruxtecan improved progression-free survival (PFS) relative to trastuzumab emtansine across all patients with HER2-positive metastatic breast cancer, including a 75% improvement in PFS among those with baseline brain metastases.
No takes yet. Share an insight, caveat, or question.
Anne Jacobson (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: